Study objectives-(l) To measure the quality of life and the loss of quality adjusted days (QADS) after suspected acute myocardial infarction in patients who received thrombolytic treatment either at home or in hospital. (2) To compare the loss of QADS as a trial endpoint with the conventional endpoints of mortality and Q-wave infarction. Design Randomised double blind parallel group trial of anistreplase (30 U given intravenously) and placebo given either at home or in hospital. Setting-Rural practices in Grampian admitting patients to teaching hospitals in Aberdeen. Patients-A total of 311 patients with suspected acute myocardial infarction and no contraindications to thrombolytic treatment seen at home within four hours ofthe onset of symptoms. Measurements and main results-Loss of quality adjusted days (QADS) in the first 100 days after suspected myocardial infarction (365 QADS=1 QALY) was the main outcome measure. Compared with later administration in hospital, anistreplase at home resulted in a relative reduction ofmortality of 49% (95% confidence interval 3,95%, 2p=0.04), and a relative reduction of 26% in the proportion of survivors with infarction who had Q-waves (95% CI 7,44%, 2p=0O007).
During the 100 day follow up, the median loss ofQADS was 25 for all patients. This loss was significantly greater in those who died than in survivors (65 v 18, 2p<0.001), and in survivors with infarction than in survivors without infarction (26 v 13, 2p<0-01) . However, there was no significant difference in loss of QADS in those with infarction with or without Q-waves (29 v 21, NS), and the median loss of QADS was not significantly different in those who had thrombolytic treatment at home or in hospital (median difference 0, 95% CI -5, +4 QADS). Conclusions-Loss ofQADS had two serious limitations as an outcome measure: it was less sensitive than mortality and it failed to reflect physiological benefit. Palliative treatment with no physiological effect would have resulted in a greater gain in QADS (or QALYs) than did early thrombolytic treatment. Extreme If it were not for the adverse effects of thrombolytic therapy, particularly the liability to cause haemorrhagic stroke, its use could be advocated for all patients with evolving infarcts whatever the size. If quality of life is used as an outcome measure, adverse effects of treatment, if they impinge on the quality or quantity of life, are included in the total. The gains and losses of therapy are therefore computed in the same currency as each other, enabling the net benefit to be calculated for any group of patients. In theory, then, quality of life has much to commend it as a trial outcome measure.
In the Grampian Region Early Anistreplase Trial (GREAT), patients with suspected acute myocardial infarction were randomly allocated to receive thrombolytic therapy at home from their general practitioners, or later, in hospital. Home treatment resulted in a median time-saving of 130 minutes which was associated with lower mortality, fewer fatal and non-fatal cardiac arrests, fewer Q-wave infarcts, and better left ventricular function; there was no evidence of infarct "abortion".2 In this paper we describe the experimental use of a quality of life measure in this trial and compare its performance with that of the conventional outcome measures that were also used.
The quality of life instrument we used is derived eight objective states of disability and four subjective states of mental distress. Every combination of disability and distress has a quality of life score, whose scale runs from 0 for death, to 1 for good health without disability and distress. To derive the scores, all combinations of disability and distress were ranked in order and given a score by 70 respondents in structured interviews. The method of classifying patients' level of disability has good reproducibility,4 but the scoring system has attracted criticism because a relatively small number of respondents who were unrepresentative of the general population were used.5
In this study the Rosser-Kind disability-distress classification is used, but in conjunction with scores obtained from about 300 subjects with a wide spread of ages and social classes, more representative ofthe general population.6 The main difference between the old and the new scores is that the new valuation places more emphasis on distress and less on disability than the old.
The Rosser-Kind index is the basis for the calculation of quality adjusted life years (QALYs).
Patients and methods Three hundred and eleven patients were entered into the trial 216 men and 95 women with a mean age 63 years. All patients were considered by their general practitioners to have a strong probability of acute myocardial infarction, having had typical chest pain for between 20 minutes and four hours. At home, patients were either given anistreplase (30 U intravenously) or placebo. All patients were admitted to hospital, where the alternative treatment to that received at home was given.
In hospital, the diagnosis was sought by electrocardiography and measurement of the myocardial isoenzyme of creatinine kinase (CK-MB). The diagnostic criteria used in the trial have been reported previously2 and the method of measuring quality of life has been described in a pilot study using the Rosser and Kind valuation matrix.'
The progress of patients in hospital was noted, the dates being recorded when patients were allowed out of bed, and discharged home. Before discharge patients were interviewed by a doctor JR) who had no clinical responsibility for them and did not give advice on rehabilitation. The purpose of the interview was to assess the quality of life before hospital admission, to request cooperation during follow up, and to give each patient a letter on which to record the dates when various activities were resumed after discharge from hospital. One month after admission patients were contacted (by JR), usually by telephone, and their progress was noted. Any readmissions to hospital during the 100 day follow up period, because of reinfarction or cardiac failure, for example, were logged in the same way as the initial admission. A final interview and examination took place three months after the suspected heart attack.
QUALITY OF LIFE SCALE Table I shows the Rosser-Kind scale as adapted for use in this study. The original valuation matrix consists of eight degrees of disability (none to unconscious; 1 to 8) combined with four degrees of mental distress (none, mild, moderate, or severe; A to D). We have omitted the highest degree of disability, which is unconsciousness, and restricted the number of possible levels of distress at the highest levels of disability, the assumption being made that moderate distress will be experienced on admission to hospital with chest pain, and mild distress will be experienced until disability improves to level 4 or better. The table may be used to record the dates of each stage of convalescence as the patient progresses from admission to hospital with suspected acute myocardial infarction (quality of life 7C=0 20), to restoration to full health with no disability or distress (quality of life 1A= 1 00). The same table is used to determine the quality of life score before the suspected heart attack.
CALCULATION OF LOST QUALITY ADJUSTED DAYS (QADS)
The quality of life score for each patient is plotted against the number of days since the onset of the illness. With each stage of convalescence, quality of life increases in a stepwise fashion, the assumption being made that after each improvement quality of life is maintained at the same level until the next change is reported. The area under the curve gives the number of QADS achieved in the 100 day follow up period. This number is subtracted from the product of the follow up period and the quality of life score before the heart attack, to give the number of QADS lost. Thus Table II gives the numbers of patients who died, who had infarction confirmed, and who had Q-waves. Thirty six patients died within 100 days of entry, 13 in the home group and 23 in the hos group. All deaths except one were patients acute myocardial infarction; the mortality ci are depicted in figure 1. The curves are sep throughout the 100 day follow up period, a end of which the mortality rate is signific higher in the hospital than in the home groul of 163 (8 0%) v 23 of 148 (15-5%) 95% CI 15%, 2p=004).
In those patients with confirmed infarction lived, more had Q-waves in the home group in the hospital group (59 of 113 (52-2%) v 66 (70 2%) 95% CI 5,31%, 2p=0007).
QUALITY OF LIFE SCORES
Median premorbid quality of life scores similar in home and hospital groups (0 91 v 0 Among survivors, the proportion of patients had not achieved their premorbid quality o score by 100 days was higher in those infarction than in those without (127 of (61-4%) ;who )f life SENSITIVITY OF QUALITY OF LIFE MEASUREMENT with The measurement of quality of life seems to be 207 sensitive to changes in living circumstances. Qual-34O_ ity of life scores were appreciably depressed at the ence, onset of the illness, and improved progressively had during the next 100 days. In the survivors, the score curves overlapped for much of their extent, suggesting that the measurement of quality of life is made with considerable precision and has good reproducibility. A lower proportion of survivors with than without confirmed infarction regained their premorbid quality of life score by the end of the follow up period. Loss of QADS was greater in those who died than in those who lived, and was greater in survivors with than in survivors without confirmed myocardial infarction. All these are findings that would be expected of a sensitive measure of quality of life.
FAILURE OF QUALITY OF LIFE SCORES TO REFLECT PHYSIOLOGICAL STATUS
There was no significant difference in lost QADS in survivors with infarction with or without Qwaves. Moreover, neither in the whole group nor in any subset was there a significant difference in lost QADS in those who had thrombolytic therapy at home rather than in hospital. These results ty suggest that the demonstrable physiological benefits of early thrombolytic therapy-smaller in mortality, since there is no separation of the quality of life curves for survivors. In constructing ---mortality curves, death is a binary state, either present or not. Death, however, results in a variable reduction in the quality of life score, depending on the premorbid score, and a variable loss of QADS, depending on when death occurs in the follow up period. Ifit occurs towards the end of tal that period it may result in the loss ofno more than the average number of QADS that are lost by survivors. On the other hand, survivors whose convalescence is particularly slow may lose as many QADS as someone who dies. The use of the quality of life scoring system cannot reflect the binary nature of death and devalues existence; the -, implied value of life is merely the absence of 100 disability or distress.' In using loss of QADS rather than mortality as an outcome measure, the distinction between those who die and those who w up. survive becomes blurred. Hence, the quality of life score and loss of QADS are less sensitive than mortality as outcome measures. The failure of physiological benefit to be trai lated into improved quality of life scores conr about because the rate of return to norn activities after myocardial infarction is r governed by physiological capacity, but by cust and convention. In addition, the quality of I scoring system places considerable emphasis mental distress. Thus, at any level of disability, t quality of life score is approximately halved distress increases from none to severe. But l degree of distress occasioned by a heart attacL not closely related to the size ofthe infarct, and v be much the same whether the infarct is small large, non-Q-wave or Q-wave. It might be argued that we have used the quality of life scoring system to measure short term changes in a way that it was never meant to be used. -
The separation of the quality of life curves seen at the end of the 100 day follow up period would continue if the follow up period were longer. Assuming no change in individual quality of life scores after 100 days, the loss of QADS by those who had died would increase with the passage of time until the loss in the hospital group would become significantly greater than the loss in the home group. With a longer follow up period, -therefore, quality of life measurement would show 100 that home treatment was preferable to hospital treatment. But the use of a longer follow up period 100 amplifies the effect of death on loss of QADS, and sharpens the distinction between death and life, a distinction that is blurred by the use of quality of are life rather than mortality as an outcome measure. res The longer the follow up period, the more closely the measure behaves like mortality. 
